This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.

开始日期2026-01-01

申办/合作机构

Stony Brook University

NCT05367362

/ Not yet recruiting临床2期IIT

Efficacy of Minocycline in Improving Neurological Outcomes of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke

The study will be a prospective, randomized, double- blinded placebo, single center pilot clinical trial. Patients with acute ischemic stroke due to large vessel occlusion undergoing endovascular thrombectomy will be included. The treatment group will receive 200 mg intravenous/oral minocycline hydrochloride in addition to endovascular thrombectomy for a total of 21 days. The control group will receive standard medical and endovascular care along with a similar looking placebo. Patients will be randomized to the treatment or control group by the Pharmacy eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients further minimizing the bias. Through randomization we expect to achieve two groups that are comparable in their baseline clinical characteristics.

开始日期2025-12-01

申办/合作机构

State University of New York at Buffalo

NCT07082855

/ Not yet recruiting临床3期IIT

A Multicenter, Double-Blind, Randomized Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa

This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety?100mg/d, 200mg/d) for Retinitis pigmentosa and to find the optimal treatment dose.

开始日期2025-07-15

申办/合作机构

中山大学中山眼科中心

100 项与盐酸米诺环素相关的临床结果

登录后查看更多信息

100 项与盐酸米诺环素相关的转化医学

登录后查看更多信息

100 项与盐酸米诺环素相关的专利（医药）

登录后查看更多信息

7,279

项与盐酸米诺环素相关的文献（医药）

2025-12-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Protective effects of minocycline on dermal fibroblast cells from oxidant and apoptotic effects of H2O2: A comprehensive analysis with Raman spectroscopy and data-driven approach

Article

作者: Celik, Nusret ; Onses, Mustafa Serdar ; Sahin, Furkan ; Sezer, Gulay

Minocycline (Mino) is an antibiotic with neuroprotective, anti-inflammatory, and antioxidant properties. This study investigated the protective effects of Mino against hydrogen peroxide (H₂O₂)-induced oxidative damage in dermal fibroblast cells and analyzed these effects using Raman spectroscopy, principal component analysis (PCA), and machine learning (ML). L929 fibroblast cells were evaluated using MTT and scratch wound-healing assays. The production of reactive oxygen species (ROS) and the process of apoptosis were evaluated through the use of 2',7'-dichlorofluorescein diacetate (DCFH-DA) and Annexin V labelling, respectively. The mRNA expression levels of Nrf2, Hmox1, Nqo1, and Col1a were analyzed through quantitative real-time polymerase chain reaction (qRT-PCR). Raman spectroscopy detected molecular alterations, while PCA and ML classified spectral variations. Mino reduced H₂O₂-induced cellular toxicity, ROS levels, and apoptosis while enhancing fibroblast migration. It significantly upregulated Nrf2 and Hmox1 mRNA under oxidative stress and increased Col1a expression when applied alone. Raman spectroscopy revealed biochemical changes in lipids, proteins, and nucleic acids. PCA distinguished treatment groups, showing Mino-treated cells closely resembled controls. The SVM attained 90.10 % classification accuracy, underscoring the efficacy of Raman-based computational analysis. The findings collectively highlight the potential of Raman spectroscopy, PCA, and ML as a sensitive, label-free approach for monitoring molecular changes, thereby supporting the therapeutic potential of Mino in oxidative stress-related therapies.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Prevalence of New Delhi Metallo-β-lactamase (blaNDM) gene in a selected population of drug-resistant clinical isolates

Article

作者: Ahmed, Iftikhar ; Ahmad, Aftab ; Saeed, Muhammad ; Shafiq, Muhammad ; Latif, Kunza ; Hyder, Muhammad Zeeshan

OBJECTIVES:

Drug-resistant Enterobacterales carrying carbapenem-resistant genes cause severe infections in clinical settings worldwide. Among these, the New Dehli Metallo-β-lactamase (bla_NDM) gene is significantly prevalent and associated with high morbidity. This study was designed to investigate the susceptibility profiling of Carbapenem-Resistant-Enterobacterales (CRE), prevalence of bla_NDM and its variants, and associated risk factors.

METHODS:

CRE isolates from a tertiary care hospital, in Islamabad, Pakistan, were identified and the susceptibility testing was performed using disc diffusion method. MICs were determined for imipenem, tigecycline, and colistin through E-strips and microbroth dilution method respectively. For molecular characterization and typing of the bla_NDM gene, PCR products were sequenced, and the phylogenetic analysis was performed using MEGA ver 6.0 software.

RESULTS:

Among 5,134 clinical samples, 42.13% (n = 2,163) yielded pathogens including 42.58% (n = 921) Enterobacterales. On further screening, 39.52% (n = 364) of Enterobacterales were identified as CRE. The bla_NDM gene was detected in 75.27% (n = 274) in CRE isolates, comprising bla_NDM-1 (44%), bla_NDM-5 (53%), and bla_NDM-7 (3%) variants. Tigecycline (86.7%) and colistin (100%) were most effective antimicrobial agents with MICs ranging from 0.064 to 8 and 0.125-1 µg/ml respectively. bla_NDM-1-harboring bacteria exhibited high antimicrobial resistance compared to bla_NDM-5 and bla_NDM-7. Cefiderocol was 75.6% and ceftazidime/avibactam with aztreonam was 97.08% effective against bla_NDM-harboring bacteria. The phylogenetic analysis indicated that bla_NDM variants showed close genetic relationships and homology to the previously described sequences in GenBank databases having diverse connection with worldwide sequences.

CONCLUSION:

The high prevalence of bla_NDM in our study has of great concern for clinical practice and public health. Clinicians are left with few therapeutic options. However, ceftazidime/avibactam with aztreonam may show therapeutic success. Continuous surveillance is crucial to monitorgenetic variations of continuously evolving bla_NDM gene, which is essential for effective clinical management.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Differential effects of minocycline on human breast epithelial cells, human breast cancer cells and their tumor hybrids

Article

作者: Weiler, Julian ; Moayed, Fuad ; Dittmar, Thomas ; Keil, Silvia

Abstract:

Background:

The antibiotic minocycline has been suggested as a potential agent in cancer therapy due to its anti-inflammatory properties and effectiveness as an NF-κB inhibitor. In previous studies, we showed that minocycline could effectively block the fusion of breast epithelial cells and cancer cells. However, its influence on breast cancer cell characteristics, including proliferation, migration, and gene expression has not yet been investigated.

Methods:

M13SV1-EGFP-Neo breast epithelial cells, HS578T-Hyg breast cancer cells and M13HS-2 and M13HS-8 tumor hybrids were used as breast (cancer) model cell lines in this study. Cells were treated with up to 50 µg/ml minocycline. An XTT assay and a colony formation assay were used to study cell proliferation. Western blot analysis and Zymography were used to examine the expression of MMP-2 and MMP-9, EMT, and stemness marker. Cell migration was measured by Scratch assay. Using a two-way ANOVA and the Tukey post-hoc test, statistical significance was determined.

Results:

Minocycline inhibited proliferation and colony formation capacity in a dose-dependent manner, whereas EMT and stemness marker expression remained unchanged in all cell lines. Zymography data showed that MMP-2 and MMP-9 expression was down-regulated M13SV1-EGFP-Neo treated with minocycline, but not in HS578T-Hyg cells or M13HS-2 and M13HS-8 tumor hybrids. Minocycline inhibited the migration of M13SV1-EGFP-Neo cells in a dose-dependent manner, while the migration of HS578T-Hyg, M13HS-2 and M13HS-8 tumor hybrid cells necessitated a minimum of 25 µg/ml minocycline,

Conclusions:

The results showed that non-malignant cells and neoplastic cells reacted differently to minocycline. This could mean that minocycline will have unwanted side effects if it is used in cancer therapy.

160

项与盐酸米诺环素相关的新闻（医药）

2025-08-11

·国家药品监督管理局

2025年08月11日药品批准证明文件送达信息

2022年11月1日起，行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照，按照相关提示自行打印。序号受理号药品名称申请人批准文号批准日期1CYHB2400439氨甲苯酸注射液湖南洞庭药业股份有限公司————2025年08月08日2CYHB2450232盐酸米诺环素片无锡凯夫制药有限公司————2025年08月08日3CYHB2450307注射用头孢噻肟钠湘北威尔曼制药股份有限公司国药准字H202581572025年08月07日4CYHB2450308注射用头孢噻肟钠湘北威尔曼制药股份有限公司————2025年08月07日5CYHB2450309注射用头孢噻肟钠湘北威尔曼制药股份有限公司————2025年08月07日6CYHB2450310注射用头孢噻肟钠湘北威尔曼制药股份有限公司————2025年08月07日7CYHB2450311注射用头孢噻肟钠湘北威尔曼制药股份有限公司————2025年08月07日8CYHB2450351注射用头孢呋辛钠海南广升誉制药有限公司————2025年08月07日9CYHB2450352注射用头孢呋辛钠海南广升誉制药有限公司————2025年08月07日10CYHB2450408注射用青霉素钠武汉久安药业有限公司————2025年08月07日11CYHB2450409注射用青霉素钠武汉久安药业有限公司————2025年08月07日12CYHB2450527盐酸哌罗匹隆片丽珠集团丽珠制药厂————2025年08月08日13CYHB2501455辛伐他汀片广东香山堂制药有限公司————2025年08月08日14CYHB2501456辛伐他汀片广东香山堂制药有限公司————2025年08月08日15CYHB2501467帕拉米韦注射液湖北美林药业有限公司————2025年08月08日16CYHB2501472注射用头孢唑肟钠山东二叶制药有限公司————2025年08月08日17CYHB2501473注射用头孢唑肟钠山东二叶制药有限公司————2025年08月08日18CYHB2501474注射用头孢唑肟钠山东二叶制药有限公司————2025年08月08日19CYZB2500317双蚁祛湿通络胶囊广西双蚁药业有限公司————2025年08月07日20CYZB2500620坤复康片陕西康惠制药股份有限公司————2025年08月06日21CYZB2500621盆炎净胶囊陕西康惠制药股份有限公司————2025年08月06日22CYZB2500634金鳝消渴颗粒贵州汉方药业有限公司————2025年08月06日23CYZB2500734润肠胶囊广州琥瑞医药科技发展有限公司————2025年08月06日24CYZB2500832乙肝健片(A、B)甘肃佛阁藏药有限公司————2025年08月06日25CYZB2500833乙肝健片甘肃佛阁藏药有限公司————2025年08月06日26CYZB2500864藿香正气胶囊山西黄河中药有限公司————2025年08月06日27CYZB2500866养胃舒软胶囊山西黄河中药有限公司————2025年08月06日28CYZB2500870复方苦木消炎片葵花药业集团湖北武当有限公司————2025年08月06日29CYZB2500923竹叶椒片兰州佛慈制药股份有限公司————2025年08月06日30CYZB2500961复方土槿皮酊福州海王金象中药制药有限公司————2025年08月07日31CYZB2500987健胃止疼五味胶囊乌兰浩特中蒙制药有限公司————2025年08月06日32CYZB2501025熊胆胶囊广东华南药业集团有限公司————2025年08月07日33CYZB2501031腰痛片陕西盘龙药业集团股份有限公司————2025年08月07日34CYZB2501033杞菊地黄胶囊陕西盘龙药业集团股份有限公司————2025年08月07日35CYZB2501036骨松宝片陕西盘龙药业集团股份有限公司————2025年08月07日36CYZB2501037接骨续筋片陕西盘龙药业集团股份有限公司————2025年08月07日37CYZB2501462银花感冒颗粒江西青峰药业有限公司————2025年08月06日38CYZB2501463益母草颗粒江西青峰药业有限公司————2025年08月06日39CYZB2501465肾石通颗粒江西青峰药业有限公司————2025年08月06日40CYZB2501466胃灵颗粒江西青峰药业有限公司————2025年08月06日41CYZB2501475排石利胆颗粒江西青峰药业有限公司————2025年08月06日42CYZB2501476陆英颗粒江西青峰药业有限公司————2025年08月06日43CYZB2501477宫炎康颗粒江西青峰药业有限公司————2025年08月06日44CYZB2501478阿归养血颗粒江西青峰药业有限公司————2025年08月06日45JTH2500110阿法骨化醇青松（天津）制药有限公司————2025年08月08日46JTH2500115依维莫司片泊诺（天津）创新医药研究有限公司————2025年08月08日47JTH2500116玛巴洛沙韦片上海罗氏制药有限公司————2025年08月08日48JYHB2400511富马酸贝达喹啉片西安杨森制药有限公司————2025年08月08日49JYHB2500211注射用盐酸依拉环素云顶新耀医药科技有限公司————2025年08月08日

申请上市临床申请核酸药物

2025-08-07

·PipelineReview

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN ® and REZZAYO™. The proposed acquisition will expand CorMedix’s team and commercial platform, and increase the commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO™ (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate). REZZAYO™ is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. The completion of the Phase III study for REZZAYO™ is expected in 1H 2026. “This acquisition is a transformational step in the evolution of CorMedix, providing an attractive revenue base of highly synergistic assets, as well as multiple opportunities to drive future growth. We are excited to acquire Melinta, which enables us to expand our product portfolio in the hospital space while delivering therapies to patients with high unmet need,” said Joseph Todisco, CEO of CorMedix Inc. “I would like to congratulate Christine Ann Miller, Melinta Therapeutics President & CEO, on building a high-performing organization. The combination with Melinta creates a formidable and diversified specialty platform with a deep and experienced team in the hospital acute care and infectious disease arena. This transaction reflects the type of high-impact, cash-flow generating opportunities we are targeting and strengthens our position to further expand, as we strive to create shareholder value through both organic growth and additional acquisitions in the future.” “The synergistic combination of Melinta and CorMedix represents an exciting new chapter in our company’s evolution,” said Christine Ann Miller, President and CEO of Melinta Therapeutics. “Over the past five years, we have built a robust commercial infrastructure with a high-performing team, deep expertise, and relationships within the hospital and acute care ecosystem, while achieving significant revenue growth and sustained profitability. CorMedix recognizes not just our innovative therapies, but the exceptional capabilities of our organization. I’m confident that Melinta’s commercial excellence and proven track record will augment CorMedix’s team and track record of operational execution and success, to create an even stronger platform for future growth.” Strategic and Financial Benefits Terms and Financing Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders of Deerfield Management Company, L.P. (“Deerfield”). The cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing with high quality healthcare focused institutional investors, including Deerfield, the terms of which will be described in a Current Report on Form 8-K to be filed by the Company today. The agreement contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix’s election) for the FDA approval of the expanded indication of REZZAYO™ for prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantation, if this milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO™ U.S. net sales and low-single-digit royalties on MINOCIN ® U.S. net sales. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the ‘HSR Act’). The Company expects the transaction to close as early as September 1, 2025. Full Year Financial Guidance Advisors Moelis & Company LLC is acting as exclusive financial advisor for CorMedix in connection with the acquisition of Melinta and sole placement agent for convertible debt financing. Willkie Farr & Gallagher LLP is acting as legal advisor to CorMedix in connection with the acquisition of Melinta and the convertible debt financing. RBC Capital Markets is acting as a financial advisor to CorMedix in connection with the convertible debt financing. Goodwin Procter LLP is acting as a legal advisor to Moelis & Company LLC for the convertible debt financing. Conference Call and Webcast Information Management will host a conference call and a live webcast today, August 7, 2025, at 8:30 a.m. ET, to discuss the transaction and CorMedix’s second quarter 2025 financial results. The conference call can be accessed by dialing 1-844-676-2922 from the United States or 1-412-634-6840 internationally. The live webcast will be accessible in the “ Presentations & Events ” section of the CorMedix Investor Relations website or using the following Webcast Link . About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath ® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath ® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath ® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com . About Melinta Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: MINOCIN ® (minocycline), REZZAYO™ (rezafungin), VABOMERE ® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), and TOPROL-XL ® (metoprolol succinate). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit www.melinta.com . SOURCE: CorMedix

上市批准临床3期并购引进/卖出

2025-08-01

·国家药品监督管理局

国家药监局公布药品说明书适老化及无障碍改革试点名单（第五批）

根据《国家药监局关于发布药品说明书适老化及无障碍改革试点工作方案的公告》（2023年第142号），省级药品监管部门和国家药监局药品审评中心报送了参与试点的药品上市许可持有人和药品名单（第五批），现予公布。序号药品名称上市许可持有人1维格列汀片华润赛科药业有限责任公司2氨氯地平阿托伐他汀钙片华润赛科药业有限责任公司3奥美沙坦酯氢氯噻嗪片华润赛科药业有限责任公司4缬沙坦氨氯地平片（I）华润赛科药业有限责任公司5米拉贝隆缓释片华润赛科药业有限责任公司6非那雄胺片华润赛科药业有限责任公司7奥美沙坦酯氨氯地平片华润赛科药业有限责任公司8格列齐特缓释片津药达仁堂集团股份有限公司新新制药厂9硫酸氨基葡萄糖胶囊天津天士力圣特制药有限公司10培哚普利吲达帕胺片施维雅（天津）制药有限公司11妇科回生丸北京同仁堂天然药物（唐山）有限公司12七宝美髯丸北京同仁堂天然药物（唐山）有限公司13金牛眼药河北金牛药业科技有限公司14特灵眼药河北金牛药业科技有限公司15复方甲硝唑阴道栓河北金牛药业科技有限公司16牛黄解毒片山西华康药业股份有限公司17三黄片山西华康药业股份有限公司18盐酸氟西汀胶囊山西仟源医药集团股份有限公司19盐酸舍曲林片山西仟源医药集团股份有限公司20磷霉素氨丁三醇散山西仟源医药集团股份有限公司21双歧杆菌乳杆菌三联活菌片内蒙古双奇药业股份有限公司22阴道用乳杆菌活菌胶囊内蒙古双奇药业股份有限公司23麝香通心滴丸内蒙古康恩贝药业有限公司24养血安神片内蒙古大唐药业股份有限公司25康复春口服液内蒙古大唐药业股份有限公司26天麻丸内蒙古大唐药业股份有限公司27六味地黄丸内蒙古大唐药业股份有限公司28参竹精胶囊内蒙古京新药业有限公司29六味地黄丸内蒙古京新药业有限公司30明目地黄丸内蒙古天奇中蒙制药股份有限公司31知柏地黄丸内蒙古天奇中蒙制药股份有限公司32六味地黄丸内蒙古天奇中蒙制药股份有限公司33柏子养心丸内蒙古天奇中蒙制药股份有限公司34养阴清肺丸内蒙古天奇中蒙制药股份有限公司35艾地骨化醇软胶囊大连美创药业有限公司36西尼地平软胶囊大连美创药业有限公司37阿奇霉素片辉瑞制药科技有限公司38阿奇霉素干混悬剂辉瑞制药科技有限公司39阿托伐他汀钙片晖致制药（大连）有限公司40苯磺酸氨氯地平片晖致制药（大连）有限公司41外用红色诺卡氏菌细胞壁骨架辽宁天安生物制药股份有限公司42左氧氟沙星片长春海悦药业股份有限公司43他达拉非片长春海悦药业股份有限公司44苯磺酸氨氯地平片长春海悦药业股份有限公司45非诺贝酸片长春海悦药业股份有限公司46缬沙坦氨氯地平片（I）长春海悦药业股份有限公司47伏立康唑片长春海悦药业股份有限公司48拉米夫定片长春海悦药业股份有限公司49孟鲁司特钠颗粒长春海悦药业股份有限公司50艾司奥美拉唑镁碳酸氢钠胶囊长春海悦药业股份有限公司51阿奇霉素干混悬剂长春海悦药业股份有限公司52厄贝沙坦片修正药业集团股份有限公司53通窍鼻炎片修正药业集团股份有限公司54感冒清热颗粒修正药业集团股份有限公司55复方氨酚烷胺片修正药业集团股份有限公司56清肺抑火片修正药业集团股份有限公司57缬沙坦氨氯地平片（I）江苏万高药业股份有限公司58瑞舒伐他汀钙片江苏万高药业股份有限公司59厄贝沙坦氢氯噻嗪分散片江苏万高药业股份有限公司60厄贝沙坦氢氯噻嗪片江苏万高药业股份有限公司61盐酸奥洛他定颗粒江苏万高药业股份有限公司62缬沙坦氢氯噻嗪片江苏万高药业股份有限公司63阿司匹林肠溶片江苏万高药业股份有限公司64磷酸奥司他韦干混悬剂江苏万高药业股份有限公司65盐酸二甲双胍格列吡嗪片德全药品(江苏)股份有限公司66酮咯酸氨丁三醇片德全药品(江苏)股份有限公司67黄葵胶囊苏中药业集团股份有限公司68达格列净片阿斯利康药业（中国）有限公司69二甲双胍格列吡嗪胶囊卓和药业集团股份有限公司70依折麦布片常州制药厂有限公司71左乙拉西坦缓释片常州制药厂有限公司72他达拉非片常州制药厂有限公司73利伐沙班片常州制药厂有限公司74替格瑞洛片常州制药厂有限公司75塞来昔布胶囊常州制药厂有限公司76左甲状腺素钠片默克制药（江苏）有限公司77富马酸比索洛尔片默克制药（江苏）有限公司78盐酸二甲双胍片默克制药（江苏）有限公司79盐酸二甲双胍缓释片默克制药（江苏）有限公司80盐酸丁螺环酮片江苏恩华药业股份有限公司81硫酸艾玛昔替尼片江苏恒瑞医药股份有限公司82马来酸吡咯替尼片江苏恒瑞医药股份有限公司83甲磺酸阿美替尼片江苏豪森药业集团有限公司84聚乙二醇洛塞那肽注射液江苏豪森药业集团有限公司85达比加群酯胶囊南京正大天晴制药有限公司86奥美沙坦酯氨氯地平片南京正大天晴制药有限公司87硫酸氢氯吡格雷片南京正大天晴制药有限公司88厄贝沙坦氢氯噻嗪片南京正大天晴制药有限公司89依达拉奉右莰醇舌下片先声药业有限公司90乙酰半胱氨酸泡腾片江苏安必生制药有限公司91艾司奥美拉唑镁肠溶胶囊江苏中邦制药有限公司92氟比洛芬凝胶贴膏乐明药业(苏州)有限公司93洛索洛芬钠凝胶贴膏乐明药业(苏州)有限公司94盐酸莫西沙星片扬子江药业集团江苏紫龙药业有限公司95泊沙康唑肠溶片江苏海岸药业有限公司96左氧氟沙星片江苏悦兴医药技术有限公司97富马酸替诺福韦二吡呋酯片苏州弘森药业股份有限公司98盐酸度洛西汀肠溶胶囊宁波美诺华天康药业有限公司99阿卡波糖咀嚼片杭州中美华东制药有限公司100百令片杭州中美华东制药有限公司101奥利司他胶囊杭州中美华东制药有限公司102固本咳喘颗粒杭州中美华东制药有限公司103奥美拉唑碳酸氢钠胶囊杭州中美华东制药有限公司104环孢素口服溶液杭州中美华东制药有限公司105西罗莫司口服溶液杭州中美华东制药有限公司106他克莫司缓释胶囊杭州中美华东制药有限公司107他克莫司软膏杭州中美华东制药有限公司108吗替麦考酚酯干混悬剂杭州中美华东制药有限公司109西格列汀二甲双胍片（I）杭州中美华东制药有限公司110西格列汀二甲双胍片（II）杭州中美华东制药有限公司111卡格列净片杭州中美华东制药有限公司112马昔腾坦片杭州中美华东制药有限公司113吲哚布芬片杭州中美华东制药有限公司114替格瑞洛片浙江诺得药业有限公司115盐酸米诺环素胶囊瀚晖制药有限公司116厄贝沙坦片瀚晖制药有限公司117氟伐他汀钠胶囊瀚晖制药有限公司118普伐他汀钠片瀚晖制药有限公司119甲泼尼龙片瀚晖制药有限公司120枸橼酸托法替布片宏越科技（湖州）有限公司121左氧氟沙星片浙江普洛康裕制药有限公司122琥珀酸美托洛尔缓释片浙江普洛康裕制药有限公司123枸橼酸托法替布片浙江施强制药有限公司124盐酸文拉法辛缓释胶囊杭州康恩贝制药有限公司125佐米曲普坦片杭州康恩贝制药有限公司126铝碳酸镁咀嚼片杭州康恩贝制药有限公司127萘普生肠溶微丸胶囊杭州康恩贝制药有限公司128蒙脱石散杭州康恩贝制药有限公司129格列齐特片（II）浙江京新药业股份有限公司130替米沙坦片浙江京新药业股份有限公司131托拉塞米片浙江华海药业股份有限公司132氯沙坦钾氢氯噻嗪片浙江华海药业股份有限公司133二甲双胍恩格列净片（I）浙江华海药业股份有限公司134二甲双胍恩格列净片（VI）浙江华海药业股份有限公司135利格列汀二甲双胍片（II）浙江华海药业股份有限公司136他克莫司软膏福元药业有限公司137磷酸奥司他韦胶囊山东新时代药业有限公司138阿瑞匹坦胶囊山东新时代药业有限公司139盐酸伊伐布雷定片山东新时代药业有限公司140磷酸西格列汀片山东新时代药业有限公司141他达拉非片山东新时代药业有限公司142阿立哌唑片山东京卫制药有限公司143盐酸文拉法辛缓释胶囊山东京卫制药有限公司144盐酸舍曲林片山东京卫制药有限公司145阿戈美拉汀片山东京卫制药有限公司146马来酸氟伏沙明片山东京卫制药有限公司147盐酸鲁拉西酮片山东京卫制药有限公司148富马酸喹硫平缓释片山东京卫制药有限公司149健脑补肾丸荣昌制药（淄博）有限公司150甜梦胶囊荣昌制药（淄博）有限公司151雷贝拉唑钠肠溶片山东新华制药股份有限公司152阿托伐他汀钙片山东新华制药股份有限公司153布洛芬缓释胶囊山东新华制药股份有限公司154缬沙坦氨氯地平片山东新华制药股份有限公司155苯磺酸左氨氯地平片山东新华制药股份有限公司156厄贝沙坦片山东新华制药股份有限公司157厄贝沙坦氢氯噻嗪片山东新华制药股份有限公司158苯磺酸氨氯地平片山东新华制药股份有限公司159降脂宁颗粒湖南状元制药有限公司160通脉颗粒湖南状元制药有限公司161风寒感冒颗粒江右制药（常德）有限公司162健胃消食片江右制药（常德）有限公司163木香顺气丸江右制药（常德）有限公司164开胸顺气丸江右制药（常德）有限公司165三七片江右制药（常德）有限公司166乳果糖口服溶液江右制药（常德）有限公司167铝碳酸镁咀嚼片江右制药（常德）有限公司168麻仁胶囊江右制药（常德）有限公司169西青果颗粒江右制药（常德）有限公司170补肾养血丸江右制药（常德）有限公司171茶碱缓释片湖南绅泰春制药股份有限公司172磷酸奥司他韦胶囊海南亚洲制药股份有限公司173庆大霉素普鲁卡因维B12颗粒海南亚洲制药服份有限公司174多潘立酮片海南亚洲制药服份有限公司175银杏叶片海南亚洲制药服份有限公司176硫酸羟氯喹片重庆博腾药业有限公司177洛索洛芬钠口服溶液重庆华邦制药有限公司178盐酸氨溴索口崩片重庆康刻尔制药股份有限公司179氯雷他定口腔崩解片重庆康刻尔制药股份有限公司180铝碳酸镁颗粒（双跨）重庆康刻尔制药股份有限公司181黄藤素胶囊重庆康刻尔制药股份有限公司182格列齐特胶囊重庆康刻尔制药股份有限公司183二甲双胍恩格列净片（I）重庆希韦医药科技有限公司184二甲双胍恩格列净片（VI）重庆希韦医药科技有限公司185左氧氟沙星片重庆药谷制药有限公司186盐酸羟考酮缓释片西南药业股份有限公司187异烟肼片西南药业股份有限公司188氢溴酸西酞普兰片西南药业股份有限公司189烟酸缓释片西南药业股份有限公司190辛伐他汀片西南药业股份有限公司191阿莫西林分散片西南药业股份有限公司192青霉素VK片西南药业股份有限公司193阿莫西林胶囊西南药业股份有限公司194地高辛片西南药业股份有限公司195盐酸异丙嗪片西南药业股份有限公司196喷托维林氯化铵片西南药业股份有限公司197甲磺酸雷沙吉兰片重庆华森制药股份有限公司198鹿仙补肾片云南康恩贝希陶药业有限公司199感冒疏风颗粒云南康恩贝希陶药业有限公司200肠舒片云南康恩贝希陶药业有限公司201龙金通淋胶囊云南康恩贝希陶药业有限公司202三七药酒云南康恩贝希陶药业有限公司203感冒清热颗粒云南康恩贝希陶药业有限公司204小儿止咳糖浆云南康恩贝希陶药业有限公司205消炎止咳片云南康恩贝希陶药业有限公司206降脂宁颗粒云南康恩贝希陶药业有限公司207金砂五淋丸云南康恩贝希陶药业有限公司208红药胶囊云南康恩贝希陶药业有限公司209红草止鼾胶囊云南康恩贝希陶药业有限公司210萆薢分清丸云南康恩贝希陶药业有限公司211妇炎舒片云南康恩贝希陶药业有限公司212益肾健骨片云南康恩贝希陶药业有限公司213血塞通分散片云南植物药业有限公司214七叶神安片云南植物药业有限公司215三七龙血竭胶囊云南圣科药业有限公司216骨痛灵酊云南圣科药业有限公司217培哚普利氨氯地平片（III）LESLABORATOIRESSERVIER218盐酸贝尼地平片KyowaKirinCo.,Ltd219达格列净二甲双胍缓释片（I）AstraZenecaAB220达格列净二甲双胍缓释片（II）AstraZenecaAB221达格列净二甲双胍缓释片（III）AstraZenecaAB222达格列净二甲双胍缓释片（IV）AstraZenecaAB

高管变更

100 项与盐酸米诺环素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00850	盐酸米诺环素	J01AA08 A01AB23	DB01017

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
玫瑰痤疮	美国	Journey Medical Corp.	2020-05-28
寻常痤疮	美国	Bausch Health US LLC	2006-05-08
炭疽	日本	Pfizer Japan, Inc.	2002-03-06
感染	中国	海口市制药厂有限公司	1992-01-01
地方性斑疹伤寒	日本	Pfizer Japan, Inc.	1989-09-01
鹦鹉热	日本	Pfizer Japan, Inc.	1985-11-05
急性支气管炎	日本	Pfizer Japan, Inc.	1979-04-20
细菌性阴道炎	日本	Pfizer Japan, Inc.	1979-04-20
膀胱炎	日本	Pfizer Japan, Inc.	1979-04-20
泪囊炎	日本	Pfizer Japan, Inc.	1979-04-20
附睾炎	日本	Pfizer Japan, Inc.	1979-04-20
淋病	日本	Pfizer Japan, Inc.	1979-04-20
睑腺炎	日本	Pfizer Japan, Inc.	1979-04-20
感染性肠炎	日本	Pfizer Japan, Inc.	1979-04-20
子宫内感染	日本	Pfizer Japan, Inc.	1979-04-20
颌骨炎症	日本	Pfizer Japan, Inc.	1979-04-20
喉炎	日本	Pfizer Japan, Inc.	1979-04-20
肺脓肿	日本	Pfizer Japan, Inc.	1979-04-20
淋巴结炎	日本	Pfizer Japan, Inc.	1979-04-20
乳腺炎	日本	Pfizer Japan, Inc.	1979-04-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
种植体周围炎	临床3期	美国	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	德国	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	瑞典	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	英国	OraPharma, Inc.	2012-04-01
慢性牙周炎	临床3期	美国	Sunstar Americas, Inc.	2006-01-01
侵袭性牙周炎	临床3期	美国	OraPharma, Inc.	2004-01-01
脓疱疮	临床2期	以色列	VYNE Therapeutics, Inc.	2010-08-01
肌萎缩侧索硬化	临床2期	美国	Pfizer Inc.	2006-07-01
急性肾损伤	临床1期	德国	Rempex Pharmaceuticals, Inc.	2017-05-29
过敏性皮肤反应	临床1期	-	VYNE Therapeutics, Inc.	2016-09-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Phase II Trial Evaluating Minocycline for Geographic Atrophy (Pubmed \| Ophthalmol Sci)	临床2期	地图样萎缩	30	Minocycline 100 mg	鹹獵齋襯顧蓋齋簾餘淵(顧衊鬱襯鏇鏇壓顧繭獵) = 糧廠艱壓積蓋鑰艱糧齋鏇餘窪鏇簾網構醖網蓋 (襯齋繭構獵鏇壓糧鏇蓋, 0.85) 更多	不佳	2025-09-01
NCT02213575 (CTgov)	临床2期	高血压	5	Minocycline (Minocycline Treatment Group)	獵願衊繭襯膚鬱鑰艱鹹(製鹹鹽鑰鏇遞網範製繭) = 願夢構淵觸網衊構觸廠醖鹹構觸選繭鑰糧糧膚 (艱願網鑰壓淵遞憲夢壓, 0.0292) 更多	-	2025-07-01
				minocycline (Control)	觸製鹽顧遞範窪糧憲壓(廠憲衊遞窪簾鑰鏇餘繭) = 構獵憲蓋製襯糧築簾網構遞廠膚構廠網範鹽顧 (窪鑰獵艱願壓鑰衊簾鹽, 觸廠鑰窪積構鬱壓憲廠 ~ 鹹鹽顧夢遞艱憲蓋鏇網) 更多
NCT05343455 \| NCT05296629 (MVOR-2, Company_Website) 人工标引	临床3期	玫瑰痤疮	653	Emrosi (MVOR-1)	鏇簾餘膚積醖糧鹽顧觸(鏇鑰齋製蓋齋艱醖鏇獵) = 衊遞憲壓鹹鏇鏇積襯鑰廠觸糧鹽淵窪窪遞願鬱 (壓觸構願獵簾壓網簾淵 ) 更多	积极	2025-06-20
				Doxycycline (MVOR-1)	鏇簾餘膚積醖糧鹽顧觸(鏇鑰齋製蓋齋艱醖鏇獵) = 製齋範簾繭觸鹽鹹廠遞廠觸糧鹽淵窪窪遞願鬱 (壓觸構願獵簾壓網簾淵 ) 更多
NCT03106740 (IGNITE, CTgov)	临床2期	腰痛 \| 急性腰痛 \| 慢性疼痛 ... 更多	60	Magnetic Resonance-Positron Emission Tomography Imaging+Minocycline Hydrochloride 100mg Capsule (Minocycline Arm)	鑰繭遞選製醖鹽餘顧蓋(艱衊醖鏇廠鹽鹽淵夢鏇) = 蓋夢窪壓簾淵糧鹹衊鬱鬱遞夢壓範構簾蓋膚獵 (鏇積鹽鹹鑰遞築醖鏇遞, 0.051) 更多	-	2025-05-11
				Magnetic Resonance-Positron Emission Tomography Imaging (Placebo Arm)	鑰繭遞選製醖鹽餘顧蓋(艱衊醖鏇廠鹽鹽淵夢鏇) = 獵醖醖網憲製夢廠獵願鬱遞夢壓範構簾蓋膚獵 (鏇積鹽鹹鑰遞築醖鏇遞, 0.056) 更多
NCT02203552 (CTgov)	临床2期	复发性乳腺癌 \| 抑郁症 \| 焦虑症 ... 更多	56	laboratory biomarker analysis+minocycline hydrochloride (Arm I (Minocycline Hydrochloride))	糧壓鑰衊壓糧糧廠簾艱(選築鬱壓蓋夢糧齋鏇膚) = 淵構網壓製衊簾鹹鏇衊衊簾遞壓齋餘襯網鏇鏇 (壓願窪鏇範遞廠糧築鑰, 製築獵壓艱廠淵憲夢蓋 ~ 淵襯範廠簾鬱築蓋鬱艱) 更多	-	2025-01-08
				placebo (Arm II (Placebo))	糧壓鑰衊壓糧糧廠簾艱(選築鬱壓蓋夢糧齋鏇膚) = 遞夢鬱襯遞淵齋顧廠鏇衊簾遞壓齋餘襯網鏇鏇 (壓願窪鏇範遞廠糧築鑰, 觸觸獵鬱鏇醖顧壓獵糧 ~ 願範餘壓鏇遞艱醖衊蓋) 更多
NCT05296629 (MVOR-1, CTgov)	临床3期	玫瑰痤疮	323	DFD-29 (DFD-29)	膚壓顧構製蓋繭鏇蓋衊 = 範網繭糧鹽艱遞選製壓鏇壓鑰憲構憲簾鬱糧範 (廠顧衊襯築繭顧獵鹹蓋, 鑰繭醖簾餘構醖餘觸憲 ~ 餘鹹憲壓鏇鬱鑰衊膚窪) 更多	-	2024-12-03
				Placebo (Placebo)	膚壓顧構製蓋繭鏇蓋衊 = 顧鬱築餘糧鹹壓製蓋鏇鏇壓鑰憲構憲簾鬱糧範 (廠顧衊襯築繭顧獵鹹蓋, 窪鬱獵觸鏇醖鑰淵繭蓋 ~ 製膚壓襯淵餘鬱醖製衊) 更多
NCT05343455 (MVOR-2, CTgov)	临床3期	玫瑰痤疮	330	DFD-29 (DFD-29)	積鏇鹹製窪築鏇壓繭夢 = 艱繭獵齋鬱廠鹽糧襯選選遞觸醖鹽製積醖艱襯 (憲廠範獵簾蓋遞餘顧積, 積廠夢窪積廠獵繭製獵 ~ 觸艱觸網淵製膚選鏇願) 更多	-	2024-12-03
				Placebo (Placebo)	積鏇鹹製窪築鏇壓繭夢 = 遞顧襯繭顧夢壓選廠積選遞觸醖鹽製積醖艱襯 (憲廠範獵簾蓋遞餘顧積, 積憲壓觸製窪觸鬱鏇艱 ~ 鹹鹹獵廠夢範衊選鹹窪) 更多
NCT05343455 \| NCT05296629 (MVOR-2, FDA_CDER) 人工标引	临床3期	玫瑰痤疮	653	EMROSI (MVOR-1)	簾選製餘網壓簾醖衊醖(範淵窪積餘鑰築壓遞憲) = 糧餘膚積鏇衊遞獵淵膚艱積鏇網艱窪鹽觸夢範 (鹹觸鹹獵簾鹽窪襯構鏇 ) 更多	积极	2024-11-13
				Doxycycline (MVOR-1)	簾選製餘網壓簾醖衊醖(範淵窪積餘鑰築壓遞憲) = 襯壓鏇艱糧膚襯衊願衊艱積鏇網艱窪鹽觸夢範 (鹹觸鹹獵簾鹽窪襯構鏇 ) 更多
CTR20211291 (NEWS) 人工标引	临床3期	寻常痤疮	-	外用4%米诺环素泡沫剂	獵淵鹽鏇構淵鬱鹽築鬱(壓蓋鹹齋願襯願簾餘糧): P-Value = <0.001 达到更多	积极	2024-07-30
				Placebo
NCT03762915 (CTgov)	临床4期	炎症	70	minocycline HCl microspheres (SRP With Minocycline HCl Microspheres)	願觸淵憲製鹹築夢襯鏇(築網遞願夢築範窪膚觸) = 繭鬱淵簾憲壓憲衊廠觸窪積壓鹽鏇願遞糧觸簾 (簾襯壓築膚廠選餘壓選, 衊製醖繭繭簾願憲鏇糧 ~ 窪觸餘艱觸鹹糧餘遞鏇) 更多	-	2024-03-25
				minocycline HCl (SRP Without Minocycline HCl Microspheres)	願觸淵憲製鹹築夢襯鏇(築網遞願夢築範窪膚觸) = 範積廠鑰繭壓膚獵觸遞窪積壓鹽鏇願遞糧觸簾 (簾襯壓築膚廠選餘壓選, 夢製獵選鏇餘齋憲鬱鏇 ~ 觸簾顧壓膚選襯遞鏇憲) 更多